Moberg Pharma
Logotype for Moberg Pharma

Moberg Pharma (MOB) investor relations material

Moberg Pharma Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Moberg Pharma
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • MOB-015 internationalization advanced with Terclara® launched in Israel, the first market outside the Nordics; preparations with Karo Healthcare progressed toward additional launches.

  • Q3 and 9M revenue increased YoY, while operating and net losses narrowed; cash and cash equivalents were SEK 204.5 million at September 30, 2026.

Financial highlights

  • Q3 net revenue was SEK 5.8 million (4.0); gross profit SEK 3.8 million (2.4); EBIT SEK -3.2 million (-6.0); net loss SEK 1.7 million (4.3).

  • 9M net revenue was SEK 16.5 million (11.5); gross profit SEK 10.8 million (6.7); EBIT SEK -9.8 million (-19.9); net loss SEK 6.3 million (14.5).

  • Diluted EPS was SEK -0.04 in Q3 (-0.09) and SEK -0.13 for 9M (-0.31).

  • Q3 other operating income of SEK 1.8 million (0.1) primarily reflected FX adjustments on USD holdings; exposure was reduced as most holdings shifted to SEK.

Outlook and guidance

  • Karo 2027 launch preparations advanced; first production batches were manufactured, with final batch release pending and initial deliveries expected around year-end.

  • Regulatory, manufacturing and supply planning are progressing in parallel; additional launches are planned over coming years, subject to local approvals.

  • MOB-015 has approvals in 14 countries; partners cover Europe, APAC, Canada, China and Israel, with Karo agreements spanning 19 European markets, four APAC countries and China.

  • A further U.S. clinical study is considered necessary before an FDA application; near-term focus remains approved and partnered markets, while study options and potential partners are evaluated.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Moberg Pharma earnings date

Logotype for Moberg Pharma
Stora Aktiedagarna 202624 Nov, 2026
Moberg Pharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Moberg Pharma earnings date

Logotype for Moberg Pharma
Stora Aktiedagarna 202624 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Moberg Pharma AB develops, manufactures and markets OTC products in the areas of footcare and oral healthcare. The company own the rights to a patented platform technology, which means that they can tailor each product exactly to the needs of each customer. The products are primarily sold through intermediaries and are developed in close collaboration with leading retailers, who sell them on their home markets. Moberg Pharma AB market some of their products directly under their own brands, or via the company's own sales force on a limited number of selected markets.